Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

BMS Chooses Houston for $2.3B Manufacturing Facility

Published

on

Bristol Myers Squibb (BMS) has selected Houston as the site for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufacturing from late development through launch by producing multiple modalities of treatments—including small molecules, biologics, and antibody-drug conjugates (ADCs)—across disease areas.

The campus will rise within Generation Park, a 4,300-acre master planned mixed-use campus. BMS’ planned campus is part of the pharma giant’s previously announced commitment to invest $40 billion over five years in U.S.-based R&D, technology, and manufacturing.

“This investment reflects our confidence in America’s continued leadership in biopharmaceutical innovation,” Christopher Boerner, PhD, BMS’ board chair and CEO, said in a statement. “We’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life.”

BMS isn’t the only pharma giant to plan a multi-billion-dollar campus at Generation Park. Eli Lilly is developing a $6.5 billion manufacturing site designed to produce active pharmaceutical ingredients for oral drugs—including Foundayo® (orforglipron), the glucagon-like peptide-1 (GLP-1) receptor agonist obesity drug.

Lilly grew its regional footprint in April by acquiring Houston startup CrossBridge Bio, a developer of next-generation dual-payload antibody-drug conjugates (ADCs), for up to $300 million.

Reshoring plans

Lilly and BMS are among U.S.-based biopharma giants that have announced plans over the past year and a half to reshore significant portions of their manufacturing operations Stateside. Companies have cited a need to meet growing demand for new treatments—and an apparent desire to avoid the 100% tariff on treatments produced outside the United States, a tariff that took effect on July 31 based on Section 232 of the Trade Expansion Act of 1962, which allows investigations into whether drug imports by multinational biopharmas threaten national security.

Section 232 was amended earlier this year to allow a president to impose restrictions on goods imports or enter into negotiations with trading partners if the U.S. Secretary of Commerce determines, following an investigation, that the quantity or other circumstance of those imports “threaten[s] to impair” U.S. national security.

The planned Houston campus, BMS said, will be modular in design, enabling the company to add and reconfigure manufacturing capacity as needed in order to develop its current and future pipeline. By being modular as well as multi-modal, BMS reasons, the Houston campus will be flexible enough to evolve with the needs of the company and particularly patients into the future.

BMS plans to create nearly 500 skilled jobs at the campus, which the company says will be designed to grow in scale, capability, and workforce for decades to come. The company also projected creating about 2,000 construction and other indirect jobs between 2027–2030 as the facility is built and brought online.

Decision factors

BMS, which is headquartered in Lawrenceville, NJ, said it selected Texas and Generation Park after conducting what it termed an extensive, competitive evaluation of multiple markets in the Central and Eastern United States.

Among key factors in the decision, according to the company, were the emerging strength of Greater Houston’s life sciences workforce, proximity to utilities and transportation infrastructure, an overall business climate conducive to long-term growth—and available incentives.

“Our decision to build this state-of-the-art manufacturing campus in Houston, TX, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” stated Karin Shanahan, a BMS EVP and the company’s chief supply chain and operations officer.

The state of Texas has extended a $4.89 million grant from its Texas Enterprise Fund to BMS and has designated the BMS Houston facility as a “qualified project” and thus eligible for incentives to be awarded through the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers,” added Gov. Greg Abbott (R), who is seeking re-election to a fourth term.

The region’s largest life-sci campus is the world’s largest medical complex, the 1,345-acre, 54 million-square-foot Texas Medical Center (TMC), home to The University of Texas MD Anderson Cancer Center and Baylor College of Medicine’s primary campus. The region is also home to six medical schools, three Tier One research universities, and specialized training programs through San Jacinto College’s NIBRT-licensed Center for Biotechnology, Lone Star College, and Texas A&M’s National Center for Therapeutics Manufacturing.

Greater Houston is home to some 28,000 life sciences jobs, according to regional industry group BioHouston, and has about eight million square feet of lab space. BioHouston’s chairman Jeff Wade told GEN that the region had scooped up about a half-billion dollars in VC funding between 2025 and the first half of 2026.

“Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” stated Steve Kean, president and CEO of the Greater Houston Partnership, a regional economic development group.

The post BMS Chooses Houston for $2.3B Manufacturing Facility appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read